MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31.

Income Overview

Net Income
-$21.674M
EPS
-$0.64
Unit: Million (M) dollars

Income Statement
2026-03-31
2025-12-31
2025-09-30
Total revenue
0 -17* 10
Research and development
17.319 15* 19.639
General and administrative
6.635 9* 3.689
Total operating expenses
23.954 24* 23.328
Loss from operations
-23.954 -41* -13.328
Change in fair value of convertible preferred stock forward
-9* -
Interest income
2.284 1* 0.862
Other expense, net
0.004 0* 0.009
Total other income, net
2.28 10* 0.853
Net loss
-21.674 -31 -12.475
Basic EPS
-0.64 -2.931 -8.07
Diluted EPS
-0.64 -2.931 -8.07
Basic Average Shares
33,670,148 10,728,262 1,545,010
Diluted Average Shares
33,670,148 10,728,262 1,545,010
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Interest income$2.284M Net loss-$21.674M Total other income,net$2.28M Other expense, net$0.004M Loss from operations-$23.954M Total operatingexpenses$23.954M Research and development$17.319M General andadministrative$6.635M

Evommune, Inc. (EVMN)

Evommune, Inc. (EVMN)